Targets › TRBV9
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Immunology; next expected readout Jun 2027.
V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition. Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. (UniProt, A0A0B4J1U6)
Open in Phaseline: the race on TRBV9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biocad | BCD-180 anti-TRBV9 monoclonal antibody | TRBV9 | Phase 3 | Axial Spondyloarthritis | Jun 2027 |
Axial Spondyloarthritis (2)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.